EDIL3 and breast carcinoma: In addition, we analyzed RNAseq of 843 patients with breast cancer from the TCGA database28, and we observe a statistical significance in the group of patients with high levels of mRNA of EDIL3 that had a shorter overall survival at 10 years (Supplementary Fig. S1).